Charles C. Wykoff, MD, PhD

Professor of Clinical Ophthalmology, Academic Institute
Full Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp
Publications

Ocular and Systemic Risk Factors for Disease Worsening Among Patients with NPDR: Post Hoc Analysis of the PANORAMA Trial
Wykoff, CC, Do, DV, Goldberg, RA, Dhoot, DS, Lim, JI, Du, W, Silva, FQ, Desai, R, Moini, H, Reed, K, Berliner, AJ, Vitti, R & Clark, WL 2024, , Ophthalmology Retina, vol. 8, no. 4, pp. 399-408. https://doi.org/10.1016/j.oret.2023.10.016

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
PHOTON Investigators 2024, , The Lancet, vol. 403, no. 10432, pp. 1153-1163. https://doi.org/10.1016/S0140-6736(23)02577-1

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration: Up to 6-Year Analysis of the AAO IRIS® Registry
Wykoff, CC, Garmo, V, Tabano, D, Menezes, A, Kim, E, Fevrier, HB, LaPrise, A & Leng, T 2024, , Ophthalmology Science, vol. 4, no. 2, 100421, pp. 100421. https://doi.org/10.1016/j.xops.2023.100421

Magnitude of Visual Acuity Change with ETDRS versus Snellen Testing in Clinical Trials: Implications for Clinic-Based Outcomes
Salabati, M, Huang, C, Kamalipour, A, Yu, HJ, Mahmoudzadeh, R, Jeng-Miller, K, Chen, E, Shah, CP, Wykoff, CC & Hsu, J 2024, , Ophthalmology Science, vol. 4, no. 2, 100372, pp. 100372. https://doi.org/10.1016/j.xops.2023.100372

Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting
Grewal, DS, Wykoff, CC, DSouza, D, Jehl, V, Alecu, I & Jaffe, GJ 2024, , Ophthalmology Science, vol. 4, no. 1, 100361, pp. 100361. https://doi.org/10.1016/j.xops.2023.100361

Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study
Park, JG, Adrean, SD, Begaj, T, Capone, A, Charles, S, Chen, SN, Chou, HD, Cohen, MN, Corona, ST, Faia, LJ, Garg, SJ, Garretson, BR, Gregori, NZ, Haller, JA, Houghton, OM, Hsu, J, Jo, J, Kaiser, RS, Lai, CC, Mahgoub, MM, Mansoor, M, Matoba, R, Morizane, Y, Nehemy, MB, Raphaelian, PV, Regillo, CD, Ruby, AJ, Runner, MM, Sneed, SR, Sohn, EH, Spirn, MJ, Vander, JF, Wakabayashi, T, Wolfe, JD, Wykoff, CC, Yonekawa, Y, Yoon, YH & Mahmoud, TH 2024, , Ophthalmology, vol. 131, no. 1, pp. 66-77. https://doi.org/10.1016/j.ophtha.2023.08.025

Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial
Shah, M, Albini, T, Nguyen, Q, Wykoff, C, Barakat, M, Khurana, R, Kapik, B & Ciulla, TA 2024, , Ocular Immunology and Inflammation. https://doi.org/10.1080/09273948.2023.2262015

Free-Floating Pigmented Vitreous Cysts: Clinical-Histopathologic Correlation
Cao, JA, Dubovy, SR, Fan, KC, Parvus, MN, Fortun, JA & Wykoff, CC 2024, , Ophthalmic Surgery Lasers and Imaging Retina, vol. 55, no. 1, pp. 55-58. https://doi.org/10.3928/23258160-20231108-03

Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration
Mahmoudi, A, Manafi, N, Corradetti, G, Gupta Nittala, M, Emamverdi, M, Trejo Corona, S, Wykoff, CC, Sarraf, D & Sadda, SR 2024, , British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2023-324098

The ophthalmologist’s guide to evaluating the certainty of evidence using the GRADE approach
On behalf of the Retina Evidence and Trials INternational Alliance (R.E.T.I.N.A.) Study Group 2024, , Eye (Basingstoke). https://doi.org/10.1038/s41433-024-02937-1

Topographic analysis of local OCT biomarkers which predict progression to atrophy in age-related macular degeneration
Manafi, N, Mahmoudi, A, Emamverdi, M, Corradetti, G, Corona, ST, Wykoff, CC & Sadda, SVR 2024, , Graefes Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-024-06389-x

Treatment of geographic atrophy: an update on data related to pegcetacoplan
Patel, SB, Heier, JS, Chaudhary, V & Wykoff, CC 2024, , Current Opinion in Ophthalmology, vol. 35, no. 1, pp. 64-72. https://doi.org/10.1097/ICU.0000000000000845

Retinal non-perfusion: recognizing and defining what is important
Cao, JA, Al-khersan, H, Chaudhary, V & Wykoff, CC 2024, , Eye (Basingstoke). https://doi.org/10.1038/s41433-024-02981-x

Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry
Zarbin, MA, MacCumber, MW, Karcher, H, Adiguzel, E, Mayhook, A, LaPrise, A, Bilano, VL, Igwe, F, Ip, MS & Wykoff, CC 2024, , Ophthalmology and Therapy, vol. 13, no. 5, pp. 1357-1368. https://doi.org/10.1007/s40123-024-00920-3

American Society of Retina Specialists Clinical Practice Guidelines on Multimodal Imaging for Retinal Disease
Ramakrishnan, MS, Kovach, JL, Wykoff, CC, Berrocal, AM & Modi, YS 2024, , Journal of VitreoRetinal Diseases. https://doi.org/10.1177/24741264241237012

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Campochiaro, PA, Avery, R, Brown, DM, Heier, JS, Ho, AC, Huddleston, SM, Jaffe, GJ, Khanani, AM, Pakola, S, Pieramici, DJ, Wykoff, CC & Van Everen, S 2024, , The Lancet, vol. 403, no. 10436, pp. 1563-1573. https://doi.org/10.1016/S0140-6736(24)00310-6

Correction: Retinal non-perfusion: recognizing and defining what is important (Eye, (2024), 10.1038/s41433-024-02981-x)
Cao, JA, Al-khersan, H, Chaudhary, V & Wykoff, CC 2024, , Eye (Basingstoke). https://doi.org/10.1038/s41433-024-03048-7

Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis
Huang, Y, Choo, C, Hancock, S, Ciulla, TA, Wykoff, CC, Shantha, JG & Yeh, S 2024, , Journal of VitreoRetinal Diseases. https://doi.org/10.1177/24741264241246314

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study
Khanani, AM, Boyer, DS, Wykoff, CC, Regillo, CD, Busbee, BG, Pieramici, D, Danzig, CJ, Joondeph, BC, Major, JC, Turpcu, A & Kiss, S 2024, , EClinicalMedicine, vol. 67, 102394. https://doi.org/10.1016/j.eclinm.2023.102394

Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
YOSEMITE and RHINE Investigators 2024, , Ophthalmology, vol. 131, no. 6, pp. 708-723. https://doi.org/10.1016/j.ophtha.2023.12.026